

## InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103 Irvine, CA 92618

## **Technical Data Sheet**

APC conjugated Human CD25 (IL-2R) (C-Fc)

Catalog Number: 813003, 813004

Size: 25 ug, 100 ug

Target Name: IL2RA, CD25, p55

Regulatory Status: RUO

## **Product Details**

Application: FC
Format: Liquid, APC
Expression Host: CHO

Species: Human

Sources: Recombinant Human CD25 (Glu22-Cys213) with C-terminus Fc-tag is expressed in CHO

cell and conjugated to APC. **Accession Number:** P01589

Molecular Weight: The protein has a predicted molecular weight of 48.0 kDa. Under DTT-reducing

conditions, it migrates at approximately 65 kDa on SDS-PAGE prior to conjugation.

Affinity Tag: C-Fc

Formulation: 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein

Endotoxin level: Not tested

Protein Concentration: 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot

specific concentration.

Storage and Handling: Briefly centrifuge the vial upon receipt. An unopened vial may be stored at

2-8°C for up to six months.

## **Background Information**

CD25 (IL2RA), a type I transmembrane glycoprotein, is expressed on activated T cells, regulatory T cells, and dendritic cells. It binds IL-2 with low affinity on its own, but upon associating with the IL-2 receptor beta (CD122) and common gamma chain (CD132), it forms a high-affinity complex that triggers intracellular signaling pathways like MAPK and JAK/STAT. CD25 is involved in immune regulation and plays a role in autoimmune diseases, including type 1 diabetes. Soluble CD25 (sIL-2Ralpha) is released during immune responses and is a marker for tumor burden in hematological malignancies, including leukemias and lymphomas, as well as some solid tumors like melanoma and carcinomas. The presence of sIL-2Ralpha in circulation reflects tumor activity and is associated with immune modulation in cancer progression.